Improving Healthcare Delivery: The FDA and CMS Policy Alignment for Cardiovascular Devices

By Staff Writer

November 2, 2023

Navigating the FDA and CMS Policy Alignment

Two of the most important pillars supporting the healthcare sector are the Food and Drug Administration (FDA) of the United States and the Centers for Medicare & Medicaid Services (CMS). The FDA is in charge of ensuring that medical devices are both safe and effective. The coverage and benefits that are provided to CMS’s beneficiaries are decided by CMS. Because of the different legislative authorities held by these two agencies, the regulatory environment that medical device manufacturers must operate in is quite complicated.

One such program run by the FDA is called the Breakthrough Devices Program, or BDP for short. Its purpose is to encourage innovation by bestowing Breakthrough designations early on in the process of device development in order to speed up the approval process for market release. This strategy is flexible enough to accommodate a higher degree of ambiguity regarding the benefits and risks involved, provided sufficient postmarket evidence is gathered.

 

The BDP’s Impact on Healthcare Costs and Innovation

The healthcare sector has been profoundly affected as a result of the BDP’s initiatives. Since the year 2020, devices that have been given the Breakthrough designation have, in effect, automatically qualified to receive supplementary Medicare reimbursement. This change came about as a result of CMS’s decision to relax a long-standing requirement that medical devices demonstrate “substantial clinical improvement” for the people they serve (the beneficiaries).

However, the BDP’s strategy has not been without of difficulties throughout its history. The BDP might make it possible for the FDA to grant approval based on evidence that isn’t quite as stringent, including single-arm trials that focus on surrogate end goals and only have short-term follow-up. Because of this strategy, several medical devices have been granted approval based on evidence that may not be typical of Medicare recipients as a whole.

There is a significant opportunity for the BDP to serve as a catalyst for innovation in the healthcare sector. On the other hand, this raises a number of issues in terms of ensuring that the highest quality evidence is provided to guide clinical care. In order to maintain this equilibrium, the FDA and CMS will need to continue to collaborate on the improvement of their respective rules and procedures.

Reference url

Recent Posts

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

10-Year Health Plan
       

10-Year Health Plan: Transforming England’s NHS for the Future

🚀 What does the future of healthcare in England look like?

The newly unveiled 10-Year Health Plan for England sets the stage for a transformative approach, emphasizing digital innovation, community-driven care, and a shift towards preventive health. This strategic framework aims to create a more resilient and equitable NHS that prioritizes the health and well-being of all its citizens.

Curious about how these changes will impact patient experiences and workforce development? 🌟 Dive into the full article to explore the comprehensive strategies and anticipated outcomes!

#SyenzaNews #DigitalHealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.